Genomic aberrations relate early and advanced stage ovarian cancer

Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovari...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Zaal, Afra [verfasserIn] Peyrot, Wouter J. [verfasserIn] Berns, P. M. J. J. [verfasserIn] van der Burg, Maria E. L. [verfasserIn] Veerbeek, Jan H. W. [verfasserIn] Trimbos, J. Baptist [verfasserIn] Cadron, Isabelle [verfasserIn] van Diest, Paul J. [verfasserIn] van Wieringen, Wessel N. [verfasserIn] Krijgsman, Oscar [verfasserIn] Meijer, Gerrit A. [verfasserIn] Piek, Jurgen M. J. [verfasserIn] Timmers, Petra J. [verfasserIn] Vergote, Ignace [verfasserIn] Verheijen, René H. M. [verfasserIn] Ylstra, Bauke [verfasserIn] Zweemer, Ronald P. [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2012

Schlagwörter:	Oligonucleotide array Ovarian neoplasms Chromosome aberrations Neoplasm staging Prognosis

Übergeordnetes Werk:	Enthalten in: Cellular oncology - Amsterdam [u.a.] : IOS Press, 2004, 35(2012), 3 vom: 12. Mai, Seite 181-188
Übergeordnetes Werk:	volume:35 ; year:2012 ; number:3 ; day:12 ; month:05 ; pages:181-188

Links:	Volltext

DOI / URN:	10.1007/s13402-012-0077-5

Katalog-ID:	SPR031591078

Internformat


LEADER	01000caa a22002652 4500
001	SPR031591078
003	DE-627
005	20230519192019.0
007	cr uuu---uuuuu
008	201007s2012 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s13402-012-0077-5 \|2 doi
035			\|a (DE-627)SPR031591078
035			\|a (SPR)s13402-012-0077-5-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|a 570 \|q ASE
100	1		\|a Zaal, Afra \|e verfasserin \|4 aut
245	1	0	\|a Genomic aberrations relate early and advanced stage ovarian cancer
264		1	\|c 2012
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients.
650		4	\|a Oligonucleotide array \|7 (dpeaa)DE-He213
650		4	\|a Ovarian neoplasms \|7 (dpeaa)DE-He213
650		4	\|a Chromosome aberrations \|7 (dpeaa)DE-He213
650		4	\|a Neoplasm staging \|7 (dpeaa)DE-He213
650		4	\|a Prognosis \|7 (dpeaa)DE-He213
700	1		\|a Peyrot, Wouter J. \|e verfasserin \|4 aut
700	1		\|a Berns, P. M. J. J. \|e verfasserin \|4 aut
700	1		\|a van der Burg, Maria E. L. \|e verfasserin \|4 aut
700	1		\|a Veerbeek, Jan H. W. \|e verfasserin \|4 aut
700	1		\|a Trimbos, J. Baptist \|e verfasserin \|4 aut
700	1		\|a Cadron, Isabelle \|e verfasserin \|4 aut
700	1		\|a van Diest, Paul J. \|e verfasserin \|4 aut
700	1		\|a van Wieringen, Wessel N. \|e verfasserin \|4 aut
700	1		\|a Krijgsman, Oscar \|e verfasserin \|4 aut
700	1		\|a Meijer, Gerrit A. \|e verfasserin \|4 aut
700	1		\|a Piek, Jurgen M. J. \|e verfasserin \|4 aut
700	1		\|a Timmers, Petra J. \|e verfasserin \|4 aut
700	1		\|a Vergote, Ignace \|e verfasserin \|4 aut
700	1		\|a Verheijen, René H. M. \|e verfasserin \|4 aut
700	1		\|a Ylstra, Bauke \|e verfasserin \|4 aut
700	1		\|a Zweemer, Ronald P. \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Cellular oncology \|d Amsterdam [u.a.] : IOS Press, 2004 \|g 35(2012), 3 vom: 12. Mai, Seite 181-188 \|w (DE-627)392964430 \|w (DE-600)2158254-3 \|x 1875-8606 \|7 nnns
773	1	8	\|g volume:35 \|g year:2012 \|g number:3 \|g day:12 \|g month:05 \|g pages:181-188
856	4	0	\|u https://dx.doi.org/10.1007/s13402-012-0077-5 \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
951			\|a AR
952			\|d 35 \|j 2012 \|e 3 \|b 12 \|c 05 \|h 181-188

Indexfelder

author_variant	a z az w j p wj wjp p m j j b pmjj pmjjb d b m e l v dbmel dbmelv j h w v jhw jhwv j b t jb jbt i c ic d p j v dpj dpjv w w n v wwn wwnv o k ok g a m ga gam j m j p jmj jmjp p j t pj pjt i v iv r h m v rhm rhmv b y by r p z rp rpz
matchkey_str	article:18758606:2012----::eoiaertoseaealaddacdt
hierarchy_sort_str	2012
publishDate	2012
allfields	10.1007/s13402-012-0077-5 doi (DE-627)SPR031591078 (SPR)s13402-012-0077-5-e DE-627 ger DE-627 rakwb eng 610 570 ASE Zaal, Afra verfasserin aut Genomic aberrations relate early and advanced stage ovarian cancer 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients. Oligonucleotide array (dpeaa)DE-He213 Ovarian neoplasms (dpeaa)DE-He213 Chromosome aberrations (dpeaa)DE-He213 Neoplasm staging (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Peyrot, Wouter J. verfasserin aut Berns, P. M. J. J. verfasserin aut van der Burg, Maria E. L. verfasserin aut Veerbeek, Jan H. W. verfasserin aut Trimbos, J. Baptist verfasserin aut Cadron, Isabelle verfasserin aut van Diest, Paul J. verfasserin aut van Wieringen, Wessel N. verfasserin aut Krijgsman, Oscar verfasserin aut Meijer, Gerrit A. verfasserin aut Piek, Jurgen M. J. verfasserin aut Timmers, Petra J. verfasserin aut Vergote, Ignace verfasserin aut Verheijen, René H. M. verfasserin aut Ylstra, Bauke verfasserin aut Zweemer, Ronald P. verfasserin aut Enthalten in Cellular oncology Amsterdam [u.a.] : IOS Press, 2004 35(2012), 3 vom: 12. Mai, Seite 181-188 (DE-627)392964430 (DE-600)2158254-3 1875-8606 nnns volume:35 year:2012 number:3 day:12 month:05 pages:181-188 https://dx.doi.org/10.1007/s13402-012-0077-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 AR 35 2012 3 12 05 181-188
spelling	10.1007/s13402-012-0077-5 doi (DE-627)SPR031591078 (SPR)s13402-012-0077-5-e DE-627 ger DE-627 rakwb eng 610 570 ASE Zaal, Afra verfasserin aut Genomic aberrations relate early and advanced stage ovarian cancer 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients. Oligonucleotide array (dpeaa)DE-He213 Ovarian neoplasms (dpeaa)DE-He213 Chromosome aberrations (dpeaa)DE-He213 Neoplasm staging (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Peyrot, Wouter J. verfasserin aut Berns, P. M. J. J. verfasserin aut van der Burg, Maria E. L. verfasserin aut Veerbeek, Jan H. W. verfasserin aut Trimbos, J. Baptist verfasserin aut Cadron, Isabelle verfasserin aut van Diest, Paul J. verfasserin aut van Wieringen, Wessel N. verfasserin aut Krijgsman, Oscar verfasserin aut Meijer, Gerrit A. verfasserin aut Piek, Jurgen M. J. verfasserin aut Timmers, Petra J. verfasserin aut Vergote, Ignace verfasserin aut Verheijen, René H. M. verfasserin aut Ylstra, Bauke verfasserin aut Zweemer, Ronald P. verfasserin aut Enthalten in Cellular oncology Amsterdam [u.a.] : IOS Press, 2004 35(2012), 3 vom: 12. Mai, Seite 181-188 (DE-627)392964430 (DE-600)2158254-3 1875-8606 nnns volume:35 year:2012 number:3 day:12 month:05 pages:181-188 https://dx.doi.org/10.1007/s13402-012-0077-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 AR 35 2012 3 12 05 181-188
allfields_unstemmed	10.1007/s13402-012-0077-5 doi (DE-627)SPR031591078 (SPR)s13402-012-0077-5-e DE-627 ger DE-627 rakwb eng 610 570 ASE Zaal, Afra verfasserin aut Genomic aberrations relate early and advanced stage ovarian cancer 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients. Oligonucleotide array (dpeaa)DE-He213 Ovarian neoplasms (dpeaa)DE-He213 Chromosome aberrations (dpeaa)DE-He213 Neoplasm staging (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Peyrot, Wouter J. verfasserin aut Berns, P. M. J. J. verfasserin aut van der Burg, Maria E. L. verfasserin aut Veerbeek, Jan H. W. verfasserin aut Trimbos, J. Baptist verfasserin aut Cadron, Isabelle verfasserin aut van Diest, Paul J. verfasserin aut van Wieringen, Wessel N. verfasserin aut Krijgsman, Oscar verfasserin aut Meijer, Gerrit A. verfasserin aut Piek, Jurgen M. J. verfasserin aut Timmers, Petra J. verfasserin aut Vergote, Ignace verfasserin aut Verheijen, René H. M. verfasserin aut Ylstra, Bauke verfasserin aut Zweemer, Ronald P. verfasserin aut Enthalten in Cellular oncology Amsterdam [u.a.] : IOS Press, 2004 35(2012), 3 vom: 12. Mai, Seite 181-188 (DE-627)392964430 (DE-600)2158254-3 1875-8606 nnns volume:35 year:2012 number:3 day:12 month:05 pages:181-188 https://dx.doi.org/10.1007/s13402-012-0077-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 AR 35 2012 3 12 05 181-188
allfieldsGer	10.1007/s13402-012-0077-5 doi (DE-627)SPR031591078 (SPR)s13402-012-0077-5-e DE-627 ger DE-627 rakwb eng 610 570 ASE Zaal, Afra verfasserin aut Genomic aberrations relate early and advanced stage ovarian cancer 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients. Oligonucleotide array (dpeaa)DE-He213 Ovarian neoplasms (dpeaa)DE-He213 Chromosome aberrations (dpeaa)DE-He213 Neoplasm staging (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Peyrot, Wouter J. verfasserin aut Berns, P. M. J. J. verfasserin aut van der Burg, Maria E. L. verfasserin aut Veerbeek, Jan H. W. verfasserin aut Trimbos, J. Baptist verfasserin aut Cadron, Isabelle verfasserin aut van Diest, Paul J. verfasserin aut van Wieringen, Wessel N. verfasserin aut Krijgsman, Oscar verfasserin aut Meijer, Gerrit A. verfasserin aut Piek, Jurgen M. J. verfasserin aut Timmers, Petra J. verfasserin aut Vergote, Ignace verfasserin aut Verheijen, René H. M. verfasserin aut Ylstra, Bauke verfasserin aut Zweemer, Ronald P. verfasserin aut Enthalten in Cellular oncology Amsterdam [u.a.] : IOS Press, 2004 35(2012), 3 vom: 12. Mai, Seite 181-188 (DE-627)392964430 (DE-600)2158254-3 1875-8606 nnns volume:35 year:2012 number:3 day:12 month:05 pages:181-188 https://dx.doi.org/10.1007/s13402-012-0077-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 AR 35 2012 3 12 05 181-188
allfieldsSound	10.1007/s13402-012-0077-5 doi (DE-627)SPR031591078 (SPR)s13402-012-0077-5-e DE-627 ger DE-627 rakwb eng 610 570 ASE Zaal, Afra verfasserin aut Genomic aberrations relate early and advanced stage ovarian cancer 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients. Oligonucleotide array (dpeaa)DE-He213 Ovarian neoplasms (dpeaa)DE-He213 Chromosome aberrations (dpeaa)DE-He213 Neoplasm staging (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Peyrot, Wouter J. verfasserin aut Berns, P. M. J. J. verfasserin aut van der Burg, Maria E. L. verfasserin aut Veerbeek, Jan H. W. verfasserin aut Trimbos, J. Baptist verfasserin aut Cadron, Isabelle verfasserin aut van Diest, Paul J. verfasserin aut van Wieringen, Wessel N. verfasserin aut Krijgsman, Oscar verfasserin aut Meijer, Gerrit A. verfasserin aut Piek, Jurgen M. J. verfasserin aut Timmers, Petra J. verfasserin aut Vergote, Ignace verfasserin aut Verheijen, René H. M. verfasserin aut Ylstra, Bauke verfasserin aut Zweemer, Ronald P. verfasserin aut Enthalten in Cellular oncology Amsterdam [u.a.] : IOS Press, 2004 35(2012), 3 vom: 12. Mai, Seite 181-188 (DE-627)392964430 (DE-600)2158254-3 1875-8606 nnns volume:35 year:2012 number:3 day:12 month:05 pages:181-188 https://dx.doi.org/10.1007/s13402-012-0077-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 AR 35 2012 3 12 05 181-188
language	English
source	Enthalten in Cellular oncology 35(2012), 3 vom: 12. Mai, Seite 181-188 volume:35 year:2012 number:3 day:12 month:05 pages:181-188
sourceStr	Enthalten in Cellular oncology 35(2012), 3 vom: 12. Mai, Seite 181-188 volume:35 year:2012 number:3 day:12 month:05 pages:181-188
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Oligonucleotide array Ovarian neoplasms Chromosome aberrations Neoplasm staging Prognosis
dewey-raw	610
isfreeaccess_bool	true
container_title	Cellular oncology
authorswithroles_txt_mv	Zaal, Afra @@aut@@ Peyrot, Wouter J. @@aut@@ Berns, P. M. J. J. @@aut@@ van der Burg, Maria E. L. @@aut@@ Veerbeek, Jan H. W. @@aut@@ Trimbos, J. Baptist @@aut@@ Cadron, Isabelle @@aut@@ van Diest, Paul J. @@aut@@ van Wieringen, Wessel N. @@aut@@ Krijgsman, Oscar @@aut@@ Meijer, Gerrit A. @@aut@@ Piek, Jurgen M. J. @@aut@@ Timmers, Petra J. @@aut@@ Vergote, Ignace @@aut@@ Verheijen, René H. M. @@aut@@ Ylstra, Bauke @@aut@@ Zweemer, Ronald P. @@aut@@
publishDateDaySort_date	2012-05-12T00:00:00Z
hierarchy_top_id	392964430
dewey-sort	3610
id	SPR031591078
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031591078</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519192019.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2012 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13402-012-0077-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031591078</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13402-012-0077-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="a">570</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zaal, Afra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Genomic aberrations relate early and advanced stage ovarian cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oligonucleotide array</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ovarian neoplasms</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chromosome aberrations</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasm staging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peyrot, Wouter J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berns, P. M. J. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Burg, Maria E. L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Veerbeek, Jan H. W.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trimbos, J. Baptist</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cadron, Isabelle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Diest, Paul J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Wieringen, Wessel N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krijgsman, Oscar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meijer, Gerrit A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Piek, Jurgen M. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Timmers, Petra J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vergote, Ignace</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verheijen, René H. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ylstra, Bauke</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zweemer, Ronald P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Cellular oncology</subfield><subfield code="d">Amsterdam [u.a.] : IOS Press, 2004</subfield><subfield code="g">35(2012), 3 vom: 12. Mai, Seite 181-188</subfield><subfield code="w">(DE-627)392964430</subfield><subfield code="w">(DE-600)2158254-3</subfield><subfield code="x">1875-8606</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:3</subfield><subfield code="g">day:12</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:181-188</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13402-012-0077-5</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2012</subfield><subfield code="e">3</subfield><subfield code="b">12</subfield><subfield code="c">05</subfield><subfield code="h">181-188</subfield></datafield></record></collection>
author	Zaal, Afra
spellingShingle	Zaal, Afra ddc 610 misc Oligonucleotide array misc Ovarian neoplasms misc Chromosome aberrations misc Neoplasm staging misc Prognosis Genomic aberrations relate early and advanced stage ovarian cancer
authorStr	Zaal, Afra
ppnlink_with_tag_str_mv	@@773@@(DE-627)392964430
format	electronic Article
dewey-ones	610 - Medicine & health 570 - Life sciences; biology
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1875-8606
topic_title	610 570 ASE Genomic aberrations relate early and advanced stage ovarian cancer Oligonucleotide array (dpeaa)DE-He213 Ovarian neoplasms (dpeaa)DE-He213 Chromosome aberrations (dpeaa)DE-He213 Neoplasm staging (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213
topic	ddc 610 misc Oligonucleotide array misc Ovarian neoplasms misc Chromosome aberrations misc Neoplasm staging misc Prognosis
topic_unstemmed	ddc 610 misc Oligonucleotide array misc Ovarian neoplasms misc Chromosome aberrations misc Neoplasm staging misc Prognosis
topic_browse	ddc 610 misc Oligonucleotide array misc Ovarian neoplasms misc Chromosome aberrations misc Neoplasm staging misc Prognosis
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Cellular oncology
hierarchy_parent_id	392964430
dewey-tens	610 - Medicine & health 570 - Life sciences; biology
hierarchy_top_title	Cellular oncology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)392964430 (DE-600)2158254-3
title	Genomic aberrations relate early and advanced stage ovarian cancer
ctrlnum	(DE-627)SPR031591078 (SPR)s13402-012-0077-5-e
title_full	Genomic aberrations relate early and advanced stage ovarian cancer
author_sort	Zaal, Afra
journal	Cellular oncology
journalStr	Cellular oncology
lang_code	eng
isOA_bool	true
dewey-hundreds	600 - Technology 500 - Science
recordtype	marc
publishDateSort	2012
contenttype_str_mv	txt
container_start_page	181
author_browse	Zaal, Afra Peyrot, Wouter J. Berns, P. M. J. J. van der Burg, Maria E. L. Veerbeek, Jan H. W. Trimbos, J. Baptist Cadron, Isabelle van Diest, Paul J. van Wieringen, Wessel N. Krijgsman, Oscar Meijer, Gerrit A. Piek, Jurgen M. J. Timmers, Petra J. Vergote, Ignace Verheijen, René H. M. Ylstra, Bauke Zweemer, Ronald P.
container_volume	35
class	610 570 ASE
format_se	Elektronische Aufsätze
author-letter	Zaal, Afra
doi_str_mv	10.1007/s13402-012-0077-5
dewey-full	610 570
author2-role	verfasserin
title_sort	genomic aberrations relate early and advanced stage ovarian cancer
title_auth	Genomic aberrations relate early and advanced stage ovarian cancer
abstract	Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients.
abstractGer	Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients.
abstract_unstemmed	Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702
container_issue	3
title_short	Genomic aberrations relate early and advanced stage ovarian cancer
url	https://dx.doi.org/10.1007/s13402-012-0077-5
remote_bool	true
author2	Peyrot, Wouter J. Berns, P. M. J. J. van der Burg, Maria E. L. Veerbeek, Jan H. W. Trimbos, J. Baptist Cadron, Isabelle van Diest, Paul J. van Wieringen, Wessel N. Krijgsman, Oscar Meijer, Gerrit A. Piek, Jurgen M. J. Timmers, Petra J. Vergote, Ignace Verheijen, René H. M. Ylstra, Bauke Zweemer, Ronald P.
author2Str	Peyrot, Wouter J. Berns, P. M. J. J. van der Burg, Maria E. L. Veerbeek, Jan H. W. Trimbos, J. Baptist Cadron, Isabelle van Diest, Paul J. van Wieringen, Wessel N. Krijgsman, Oscar Meijer, Gerrit A. Piek, Jurgen M. J. Timmers, Petra J. Vergote, Ignace Verheijen, René H. M. Ylstra, Bauke Zweemer, Ronald P.
ppnlink	392964430
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1007/s13402-012-0077-5
up_date	2024-07-04T00:25:53.986Z
_version_	1803606036578304000
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031591078</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519192019.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2012 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13402-012-0077-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031591078</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13402-012-0077-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="a">570</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zaal, Afra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Genomic aberrations relate early and advanced stage ovarian cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oligonucleotide array</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ovarian neoplasms</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chromosome aberrations</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasm staging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peyrot, Wouter J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berns, P. M. J. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Burg, Maria E. L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Veerbeek, Jan H. W.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trimbos, J. Baptist</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cadron, Isabelle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Diest, Paul J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Wieringen, Wessel N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krijgsman, Oscar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meijer, Gerrit A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Piek, Jurgen M. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Timmers, Petra J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vergote, Ignace</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verheijen, René H. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ylstra, Bauke</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zweemer, Ronald P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Cellular oncology</subfield><subfield code="d">Amsterdam [u.a.] : IOS Press, 2004</subfield><subfield code="g">35(2012), 3 vom: 12. Mai, Seite 181-188</subfield><subfield code="w">(DE-627)392964430</subfield><subfield code="w">(DE-600)2158254-3</subfield><subfield code="x">1875-8606</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:3</subfield><subfield code="g">day:12</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:181-188</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13402-012-0077-5</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2012</subfield><subfield code="e">3</subfield><subfield code="b">12</subfield><subfield code="c">05</subfield><subfield code="h">181-188</subfield></datafield></record></collection>
score	7.4019337

Nicht das Richtige dabei?

Schreiben Sie uns!

Genomic aberrations relate early and advanced stage ovarian cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?